International collaboration to assess the risk of Guillain Barre Syndrome following Influenza A (H1N1) 2009 monovalent vaccines

Caitlin N Dodd; Silvana A Romio; Steven Black; Claudia Vellozzi; Nick Andrews; Miriam Sturkenboom; Patrick Zuber; Wei Hua; Jan Bonhoeffer; James Peter Buttery; Nigel Crawford; Genevieve Deceuninck; Corrine de Vries; Philippe De Wals; M Victoria Gutierrez-Gimeno; Harald Heijbel; Hayley Hughes; Kwan Hur; Anders Hviid; Jeffrey Kelman; Tehri Kilpi; S K Chuang; Kristine K Macartney; Melisa Rett; Vesta Richardson Lopez-Callada; Daniel Salmon; Francisco Gimenez Sanchez; Nuria Sanz; Barbara Silverman; Jann Storsaeter; Umapathi Thirugnanam; Nicoline van der Maas; Katherine Yih; Tao Zhang; Hector Izurieta

doi:10.1016/j.vaccine.2013.06.032

International collaboration to assess the risk of Guillain Barre Syndrome following Influenza A (H1N1) 2009 monovalent vaccines

Caitlin N Dodd, Silvana A Romio, Steven Black, Claudia Vellozzi, Nick Andrews, Miriam Sturkenboom, Patrick Zuber, Wei Hua, Jan Bonhoeffer, James Peter Buttery, Nigel Crawford, Genevieve Deceuninck, Corrine de Vries, Philippe De Wals, M Victoria Gutierrez-Gimeno, Harald Heijbel, Hayley Hughes, Kwan Hur, Anders Hviid, Jeffrey KelmanTehri Kilpi, S K Chuang, Kristine K Macartney, Melisa Rett, Vesta Richardson Lopez-Callada, Daniel Salmon, Francisco Gimenez Sanchez, Nuria Sanz, Barbara Silverman, Jann Storsaeter, Umapathi Thirugnanam, Nicoline van der Maas, Katherine Yih, Tao Zhang, Hector Izurieta

Paediatrics Monash Health

Research output: Contribution to journal › Article › Research › peer-review

86 Citations (Scopus)

Abstract

The global spread of the 2009 novel pandemic influenza A (H1N1) virus led to the accelerated production and distribution of monovalent 2009 Influenza A (H1N1) vaccines (pH1N1). This pandemic provided the opportunity to evaluate the risk of Guillain?Barre syndrome (GBS), which has been an influenza vaccine safety concern since the swine flu pandemic of 1976, using a common protocol among high and middle-income countries. The primary objective of this project was to demonstrate the feasibility and utility of global collaboration in the assessment of vaccine safety, including countries both with and without an established infrastructure for vaccine active safety surveillance. A second objective, included a priori, was to assess the risk of GBS following pH1N1 vaccination

Original language	English
Pages (from-to)	4448 - 4458
Number of pages	11
Journal	Vaccine
Volume	31
Issue number	40
DOIs	https://doi.org/10.1016/j.vaccine.2013.06.032
Publication status	Published - 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2013.06.032

Cite this

Dodd, C. N., Romio, S. A., Black, S., Vellozzi, C., Andrews, N., Sturkenboom, M., Zuber, P., Hua, W., Bonhoeffer, J., Buttery, J. P., Crawford, N., Deceuninck, G., de Vries, C., De Wals, P., Gutierrez-Gimeno, M. V., Heijbel, H., Hughes, H., Hur, K., Hviid, A., ... Izurieta, H. (2013). International collaboration to assess the risk of Guillain Barre Syndrome following Influenza A (H1N1) 2009 monovalent vaccines. Vaccine, 31(40), 4448 - 4458. https://doi.org/10.1016/j.vaccine.2013.06.032

@article{ffc489750d9942f29c5a15f5babc1842,

title = "International collaboration to assess the risk of Guillain Barre Syndrome following Influenza A (H1N1) 2009 monovalent vaccines",

abstract = "The global spread of the 2009 novel pandemic influenza A (H1N1) virus led to the accelerated production and distribution of monovalent 2009 Influenza A (H1N1) vaccines (pH1N1). This pandemic provided the opportunity to evaluate the risk of Guillain?Barre syndrome (GBS), which has been an influenza vaccine safety concern since the swine flu pandemic of 1976, using a common protocol among high and middle-income countries. The primary objective of this project was to demonstrate the feasibility and utility of global collaboration in the assessment of vaccine safety, including countries both with and without an established infrastructure for vaccine active safety surveillance. A second objective, included a priori, was to assess the risk of GBS following pH1N1 vaccination",

author = "Dodd, {Caitlin N} and Romio, {Silvana A} and Steven Black and Claudia Vellozzi and Nick Andrews and Miriam Sturkenboom and Patrick Zuber and Wei Hua and Jan Bonhoeffer and Buttery, {James Peter} and Nigel Crawford and Genevieve Deceuninck and {de Vries}, Corrine and {De Wals}, Philippe and Gutierrez-Gimeno, {M Victoria} and Harald Heijbel and Hayley Hughes and Kwan Hur and Anders Hviid and Jeffrey Kelman and Tehri Kilpi and Chuang, {S K} and Macartney, {Kristine K} and Melisa Rett and Lopez-Callada, {Vesta Richardson} and Daniel Salmon and Sanchez, {Francisco Gimenez} and Nuria Sanz and Barbara Silverman and Jann Storsaeter and Umapathi Thirugnanam and {van der Maas}, Nicoline and Katherine Yih and Tao Zhang and Hector Izurieta",

year = "2013",

doi = "10.1016/j.vaccine.2013.06.032",

language = "English",

volume = "31",

pages = "4448 -- 4458",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "40",

}

Dodd, CN, Romio, SA, Black, S, Vellozzi, C, Andrews, N, Sturkenboom, M, Zuber, P, Hua, W, Bonhoeffer, J, Buttery, JP, Crawford, N, Deceuninck, G, de Vries, C, De Wals, P, Gutierrez-Gimeno, MV, Heijbel, H, Hughes, H, Hur, K, Hviid, A, Kelman, J, Kilpi, T, Chuang, SK, Macartney, KK, Rett, M, Lopez-Callada, VR, Salmon, D, Sanchez, FG, Sanz, N, Silverman, B, Storsaeter, J, Thirugnanam, U, van der Maas, N, Yih, K, Zhang, T & Izurieta, H 2013, 'International collaboration to assess the risk of Guillain Barre Syndrome following Influenza A (H1N1) 2009 monovalent vaccines', Vaccine, vol. 31, no. 40, pp. 4448 - 4458. https://doi.org/10.1016/j.vaccine.2013.06.032

TY - JOUR

T1 - International collaboration to assess the risk of Guillain Barre Syndrome following Influenza A (H1N1) 2009 monovalent vaccines

AU - Dodd, Caitlin N

AU - Romio, Silvana A

AU - Black, Steven

AU - Vellozzi, Claudia

AU - Andrews, Nick

AU - Sturkenboom, Miriam

AU - Zuber, Patrick

AU - Hua, Wei

AU - Bonhoeffer, Jan

AU - Buttery, James Peter

AU - Crawford, Nigel

AU - Deceuninck, Genevieve

AU - de Vries, Corrine

AU - De Wals, Philippe

AU - Gutierrez-Gimeno, M Victoria

AU - Heijbel, Harald

AU - Hughes, Hayley

AU - Hur, Kwan

AU - Hviid, Anders

AU - Kelman, Jeffrey

AU - Kilpi, Tehri

AU - Chuang, S K

AU - Macartney, Kristine K

AU - Rett, Melisa

AU - Lopez-Callada, Vesta Richardson

AU - Salmon, Daniel

AU - Sanchez, Francisco Gimenez

AU - Sanz, Nuria

AU - Silverman, Barbara

AU - Storsaeter, Jann

AU - Thirugnanam, Umapathi

AU - van der Maas, Nicoline

AU - Yih, Katherine

AU - Zhang, Tao

AU - Izurieta, Hector

PY - 2013

Y1 - 2013

N2 - The global spread of the 2009 novel pandemic influenza A (H1N1) virus led to the accelerated production and distribution of monovalent 2009 Influenza A (H1N1) vaccines (pH1N1). This pandemic provided the opportunity to evaluate the risk of Guillain?Barre syndrome (GBS), which has been an influenza vaccine safety concern since the swine flu pandemic of 1976, using a common protocol among high and middle-income countries. The primary objective of this project was to demonstrate the feasibility and utility of global collaboration in the assessment of vaccine safety, including countries both with and without an established infrastructure for vaccine active safety surveillance. A second objective, included a priori, was to assess the risk of GBS following pH1N1 vaccination

AB - The global spread of the 2009 novel pandemic influenza A (H1N1) virus led to the accelerated production and distribution of monovalent 2009 Influenza A (H1N1) vaccines (pH1N1). This pandemic provided the opportunity to evaluate the risk of Guillain?Barre syndrome (GBS), which has been an influenza vaccine safety concern since the swine flu pandemic of 1976, using a common protocol among high and middle-income countries. The primary objective of this project was to demonstrate the feasibility and utility of global collaboration in the assessment of vaccine safety, including countries both with and without an established infrastructure for vaccine active safety surveillance. A second objective, included a priori, was to assess the risk of GBS following pH1N1 vaccination

UR - http://www.sciencedirect.com/science/article/pii/S0264410X13008104

U2 - 10.1016/j.vaccine.2013.06.032

DO - 10.1016/j.vaccine.2013.06.032

M3 - Article

VL - 31

SP - 4448

EP - 4458

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 40

ER -

International collaboration to assess the risk of Guillain Barre Syndrome following Influenza A (H1N1) 2009 monovalent vaccines

Abstract

UN SDGs

Access to Document

Other files and links

Cite this